Merck & Co. reached a deal to acquire the developer of targeted immune modulators for $1.85bn. Pandion CEO Kakkar talked to Scrip about the acquisition.

With elderly patients disproportionately facing hospitalization and death from COVID-19, success in the clinic would create an important market for the drug.

Coherus BioSciences is aiming to translate the success of its comprehensive biosimilar pegfilgrastim strategy to adalimumab, with plans to capture at least 10% of the US market upon formation in 2023. Management summarized the firm’s expectations during the company’s fourth-quarter earnings call, which revealed a downturn in pegfilgrastim sales and profitability.

A round up of COVID-19 developments, also including news on the EMA beginning a rolling review of Celltrion's antibody therapy, and progress for Novavax and Moderna in Japan.